Hisun Pharmaceutical and Pfizer launch a JV targeting the Chinese biosimilars market
March 06, 2012 | Analyst Insight
Hisun Pharmaceutical and Pfizer have signed JV framework contract with tentative name Hisun-Pfizer Pharmaceutical with registered capital of $250 million, but a total invested amount of $295 million. Hisun will hold 51% of the...
About Lux Research
Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.